Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system attacks the body’s own tissues, causing inflammation that can damage virtually any organ. An estimated 204,000 people in the United States have SLE, and 9 out of 10 of them are women. The disease is unpredictable, cycling between periods of active symptoms (flares) and stretches of relative calm, and it ranges from mild joint pain and skin rashes to life-threatening kidney or heart complications.
Why the Immune System Turns on Itself
In a healthy immune system, certain white blood cells called T cells and B cells work together to identify and destroy invaders like bacteria and viruses. In SLE, this partnership goes wrong. T cells lose their ability to distinguish the body’s own proteins from foreign threats, and they begin sending signals that push B cells to produce antibodies against the body’s own tissues. These self-targeting antibodies, called autoantibodies, latch onto healthy cells and form clusters called immune complexes that lodge in organs and trigger chronic inflammation.
The process is self-reinforcing. Overactive T cells release inflammatory signals that drive B cells to mature into antibody factories, which churn out more autoantibodies, which recruit more immune cells, which cause more tissue damage. This cycle is what makes SLE systemic: the autoantibodies travel through the bloodstream and can settle in the skin, joints, kidneys, brain, heart lining, or blood vessels.
Who Gets SLE and Why
SLE is strongly skewed by sex and race. Black and American Indian/Alaska Native women are two to three times more likely than White women to develop the disease, and they tend to have more severe cases. The reasons are a mix of genetics, hormones, and environment. Estrogen appears to play a role, which helps explain why SLE overwhelmingly affects women during their reproductive years.
No single cause has been identified, but several environmental factors are linked to triggering or worsening the disease. The strongest evidence points to silica dust exposure, cigarette smoking, oral contraceptives, and postmenopausal hormone therapy. Epstein-Barr virus (the virus behind mono) also stands out: people with SLE have significantly higher rates of past EBV infection than the general population, and the virus may kick-start autoimmunity through molecular mimicry, where viral proteins resemble the body’s own proteins closely enough to confuse the immune system. Ultraviolet light from sun exposure is a well-known trigger for disease flares, though whether it plays a role in causing SLE in the first place remains unclear.
Common Symptoms
SLE is sometimes called “the great imitator” because its symptoms overlap with many other conditions. Nonspecific complaints like fatigue, low-grade fever, poor appetite, and unintentional weight loss show up in more than 90% of patients. Skin and joint problems are nearly as common, affecting over 80%.
The most recognizable sign is the butterfly-shaped rash that spreads across the cheeks and bridge of the nose, known as a malar rash. But skin involvement can also include disc-shaped red patches, sensitivity to sunlight, mouth sores, and hair loss. Joint pain and swelling affect 80 to 90% of patients and can range from mild stiffness to full-blown arthritis, most often in the hands, wrists, and knees.
Beyond the skin and joints, SLE can cause chest pain from inflammation of the lining around the heart or lungs, headaches, difficulty concentrating (often called “lupus fog”), and blood abnormalities like low white blood cell counts, low platelet counts, or anemia. Symptoms tend to come and go, and flares can be triggered by stress, infections, or sun exposure.
Kidney Involvement
The kidneys are one of the organs most vulnerable to lupus damage. Up to half of all SLE patients develop clinically evident kidney disease at some point, a condition called lupus nephritis. Early signs often show up on routine urine tests as protein or abnormal cells in the urine, sometimes before a person notices any symptoms at all.
Lupus nephritis is graded on a six-class scale based on biopsy findings, ranging from minimal changes (class I) to advanced scarring (class VI). The severity matters enormously for treatment decisions and outlook. Between 10 and 30 percent of people with lupus nephritis eventually progress to end-stage kidney disease requiring dialysis or a transplant, which is why regular monitoring of kidney function is a core part of living with SLE.
Heart and Blood Vessel Risks
Cardiovascular disease is one of the leading causes of death in people with SLE, and the numbers are striking. Fatal heart attacks occur at three times the rate seen in age- and sex-matched people without lupus. Some studies have found the overall risk of heart attack is increased anywhere from 9- to 50-fold, depending on the population studied. This elevated risk comes from a combination of chronic inflammation damaging blood vessel walls, autoantibodies that promote clotting, and the side effects of long-term medications like corticosteroids. Traditional risk factors like smoking, high blood pressure, and menopause compound the problem.
How SLE Is Diagnosed
There is no single test that confirms lupus. Diagnosis relies on a combination of clinical signs and blood work, guided by classification criteria developed by international rheumatology organizations.
The first step is a blood test for antinuclear antibodies (ANA). A positive ANA at a titer of 1:80 or higher is the mandatory entry point for evaluation. ANA tests are highly sensitive (90 to 95% of SLE patients test positive) but not very specific, since 5 to 20% of healthy people, especially older adults, can also test positive. A positive ANA alone does not mean you have lupus; it means further testing is warranted.
From there, doctors look at more specific antibodies. Anti-double-stranded DNA antibodies have about 96% specificity for SLE but are only present in roughly half to two-thirds of patients. Anti-Smith antibodies are even more specific (99%) but less common, showing up in only 5 to 30% of cases. Complement proteins C3 and C4, which drop when the immune system is highly active, help track disease activity over time.
The current classification system, published in 2019, scores patients across seven clinical domains (including blood, kidney, skin, joints, and neurological symptoms) and three immunological domains. Each finding carries a different weight, and a total score of 10 or more out of a possible 51 classifies someone as having SLE. This weighted approach means that a person with severe kidney involvement and specific antibodies can meet the threshold even without the classic butterfly rash.
Treatment
Hydroxychloroquine, an antimalarial drug approved for SLE since 1955, is the backbone of treatment. Current guidelines recommend it for essentially all SLE patients unless they have a specific contraindication. It reduces flares, protects against organ damage over time, lowers cardiovascular risk, and helps with some of the most common complaints: fatigue, rashes, joint pain, and mouth sores. The recommended dose is no more than 5 mg per kilogram of body weight per day, with a maximum of 400 mg daily for people over 80 kg, to minimize the risk of retinal toxicity with long-term use. Regular eye exams are part of the monitoring plan.
Beyond hydroxychloroquine, treatment is tailored to which organs are affected and how active the disease is. Mild disease involving skin and joints may only need anti-inflammatory medications. Moderate to severe disease, particularly when the kidneys, brain, or blood are involved, typically requires immunosuppressive drugs that dial down the overactive immune response. Corticosteroids are often used during flares to quickly control inflammation, though doctors aim to minimize long-term use because of side effects like bone thinning, weight gain, and increased infection risk.
Living With SLE: Outlook and Survival
The prognosis for SLE has improved dramatically. In the 1950s, only about half of patients survived five years after diagnosis. Today, five-year survival exceeds 90%, roughly 85% of patients survive at least 10 years, and about 75% are alive 20 years after diagnosis. These gains come from earlier detection, better medications, and more careful monitoring of organ damage.
That said, people with SLE still face about three times the risk of dying over a 10-year period compared to the general population. The leading causes of death have shifted from uncontrolled disease activity to long-term complications, particularly cardiovascular disease and infections (partly from immunosuppressive treatment). The severity of kidney involvement remains the single strongest predictor of long-term outcomes. Staying on hydroxychloroquine, protecting your skin from UV exposure, keeping up with routine blood and urine monitoring, and managing traditional cardiovascular risk factors like blood pressure and cholesterol are the most impactful things you can do to stay ahead of the disease.